Stop wasting hours on dense SEC filings. Get AI-powered summaries of any SEC Filings in seconds. Understand key insights and risks, fast.
Currently we only process Form 8-K, 6-K, 3, 4, 144, Schedule 13D and Schedule 13G. We will support more forms in the future.
Filter by Form Type:
Industry:Biotechnologyβ
2026-07-09VOR3Power of Attorney for David Zaccardelli
This filing is a Power of Attorney granted by David Zaccardelli, a director at Vor Biopharma Inc., to Adi Osovsky, Adriana Sullivan, and Kevin Pimental. The attorneys-in-fact are authorized to execute and file necessary SEC forms (3, 4, and 5) related to securities transactions on behalf of Mr. Zaccardelli. This author...
Small CapBiotechnology
2026-07-09Vor Biopharma Inc.3Power of Attorney for David ZaccardelliDuplicate
This filing is a Power of Attorney granted by David Zaccardelli, a director at Vor Biopharma Inc., to Adi Osovsky, Adriana Sullivan, and Kevin Pimental. The attorneys-in-fact are authorized to execute and file necessary SEC forms (3, 4, and 5) related to securities transactions on behalf of Mr. Zaccardelli. This author...
Small CapBiotechnology
2026-07-08AURA3Power of Attorney for Director
This filing is an Exhibit 24.1, a Power of Attorney document for Jeremy Bender, a director at Aura Biosciences, Inc. The document appoints Conor Kilroy and Amy Elazzouzi as attorney-in-fact to execute and file necessary reports with the SEC, including Forms 3, 4, and 5, related to securities ownership, acquisition, or ...
Small CapBiotechnology
2026-07-08Aura Biosciences, Inc.3Power of Attorney for DirectorDuplicate
This filing is an Exhibit 24.1, a Power of Attorney document for Jeremy Bender, a director at Aura Biosciences, Inc. The document appoints Conor Kilroy and Amy Elazzouzi as attorney-in-fact to execute and file necessary reports with the SEC, including Forms 3, 4, and 5, related to securities ownership, acquisition, or ...
Small CapBiotechnology
2026-07-08CADL3Power of Attorney for Mark E. Sims
This filing is an exhibit detailing a Power of Attorney granted by Mark E. Sims, Chief Commercial Officer of Candel Therapeutics, Inc., to Paul Peter Tak and Charles Schoch. The attorneys-in-fact are authorized to execute various SEC filings on behalf of Mr. Sims, including Forms 3, 4, 5, Schedules 13D and 13G, and any...
Small CapBiotechnology